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Abstract 
Background: Buruli ulcer disease (BUD) is a necrotic skin neglected tropical disease (NTD) that has both a men‑
tal and physical health impact on affected individuals. Although there is increasing evidence suggesting a strong 
association between neglected tropical diseases (NTDs) and mental illness, there is a relative lack of information on 
BUD’s impact on the mental health and quality of life (QoL) of affected individuals in Ghana. This study is to assess the 
impact of BUD on mental health and quality of life of patients with active and past BUD infection, and their caregivers.
Methods: We conducted a case control study in 3 BUD endemic districts in Ghana between August and November 
2019. Face‑to‑face structured questionnaire‑based interviews were conducted on BUD patients with active and past 
infection, as well as caregivers of BUD patients using WHO Quality of Life scale, WHO Disability Assessment Schedule, 
Self‑Reporting Questionnaire, Buruli Ulcer Functional Limitation Score and Hospital Anxiety and Depression Scale data 
tools. Descriptive statistics were used to summarize the characteristics of the study participants. Participant groups 
were compared using student t test and chi‑square (χ2) or Fisher’s exact tests. Mean quality of life scores are reported 
with their respective 95% confidence intervals. Data was analysed using STATA statistical software.
Results: Our results show that BUD patients with active and past infection, along with their caregivers, face sig‑
nificant levels of distress and mental health sequelae compared to controls. Depression (P = 0.003) was more com‑
mon in participants with active (27%) and past BU infection (17%), compared to controls (0%). Anxiety was found in 
42% (11/26) and 20% (6/29) of participants with active and past BUD infection compared to 14% (5/36) of controls. 
Quality of life was also significantly diminished in active BUD infection, compared to controls. In the physical health 
domain, mean QoL scores were 54 ± 11.1 and 56 ± 11.0 (95% CI: 49.5‒58.5 and 52.2‒59.7) respectively for participants 
with active infection and controls. Similarly in the psychological domain, scores were lower for active infection than 
controls [57.1 ± 15.2 (95% CI: 50.9‒63.2) vs 64.7 ± 11.6 (95% CI: 60.8‒68.6)]. Participants with past infection had high 
QoL scores in both physical [61.3 ± 13.5 (95% CI: 56.1‒66.5)] and psychological health domains [68.4 ± 14.6 (95% CI: 
62.7‒74.0)].
Conclusions: BUD is associated with significant mental health distress and reduced quality of life in affected persons 
and their caregivers in Ghana. There is a need for integration of psychosocial interventions in the management of the 
disease.
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Background
Buruli ulcer disease (BUD) is a debilitating neglected 
tropical disease (NTD) of the skin caused by Mycobac-
terium ulcerans [1]. The disease mainly affects indi-
viduals from impoverished populations and has been 
reported in 33 countries, including parts of Asia, South 
America and the Western Pacific, although the high-
est burden countries are found in parts of Central and 
West Africa. The clinical presentation of BUD is varied 
and includes nodules, papules, oedemas, and ulcers. 
The lesions may enlarge with time to involve the bone 
and joints, which are critical sites affecting long-term 
mobility [2]. The mode of transmission of BUD remains 
unknown despite major advances in understanding 
disease mechanisms [2, 3]. BUD lesions may heal with 
significant scarring, leading to contractures and func-
tional limitations, especially in the absence of appropri-
ate early medical intervention [4].
Since 2012, there has been increasing evidence sug-
gesting a strong association between Neglected Tropi-
cal Diseases (NTDs) and mental illness, with the 
wide-ranging physical and socio-economic impacts 
of NTDs being linked to the development of common 
mental disorders such as anxiety and depression [5, 6]. 
This evidence has recently culminated in a WHO policy 
manual which advocates for the need to concentrate 
resources on researching the psychological sequelae 
of NTDs and their management, and to integrate evi-
dence-based mental health care into NTD programmes 
worldwide [7]. Per the WHO definition, mental health 
is “a state of well-being in which every individual real-
izes his or her own potential, can cope with the normal 
stresses of life, can work productively and fruitfully, 
and is able to make a contribution to his or her com-
munity” [8].
Functional limitations and stigmatizing scars from 
BUD have severe consequences on affected individu-
als. BUD patients have been reported to show a reduced 
quality of life (QoL) and high degrees of psychological co-
morbidity [5]. A Ghanaian study showed that the disease 
had been attributed to cultural and religious beliefs such 
that patients are often left socially isolated [9]. The stig-
matizing effect of BUD on individuals can be long lasting 
and patients at times are unable to interact in their com-
munities even after being healed [10], a common finding 
in other chronic skin NTDs [11–13]. Functional limita-
tion and financial burden at times require many patients 
to be supported by their families or loved ones (caregiv-
ers). Caregiving demands committing resources and time 
which may be challenging. Caregiver burden studies 
of NTDs have reported significant mental distress and 
reduced quality of life associated with performing such 
roles [13–17].
Although the mental health aspects of NTDs is a grow-
ing area of interest in the NTDs research community, 
studies to date have mainly focused on a small number 
of chronic skin NTDs (leprosy, cutaneous leishmania-
sis, and lymphatic filariasis) [6]. Most studies related to 
the psychological aspects of BUD have mainly assessed 
illness perception and societal participation [9, 13], as 
well as its socio-economic burden [10, 18]. Relatively few 
studies have assessed the mental health burden of BUD 
[19, 20]. This evidence gap has necessitated the need to 
holistically assess the impact of BUD on mental health 
of patients and their caregivers. In this study, we aimed 
to assess the effect of BUD on mental health and QoL of 




The study was approved by the Committee on Human 
Research, Publication and Ethics (CHRPE) of the 
Kwame Nkrumah University of Science and Technology 
(KNUST) with approval number CHRPE/AP/335/19. 
All participants provided written informed consent. All 
study procedures conformed with the principles guiding 
research in human subjects as set out in the Declaration 
of Helsinki [21].
Study sites and participants
This was a case control study to assess the mental distress 
associated with BUD among patients with active infec-
tion (any manifestation), past infection (i.e., scars and/
or contractures), and their caregivers. For the purposes 
of this study, we have defined BUD as active and past 
infection. A patient with active infection was defined as 
one who had been recently confirmed (in the preceding 
3 months) to have BUD and was on treatment but whose 
lesion had not yet healed. BUD patients with past infec-
tion were those diagnosed within the preceding three 
years, who had completed a course of antibiotic therapy 
for BUD and whose lesions had healed with or without 
disability. According to the WHO report on ageing and 
health, ‘a caregiver provides care and support to some-
one else; such support may include: helping with self-
care, household tasks, mobility, social participation and 
meaningful activities; offering information, advice and 
Keywords: Mental health, Depression, Anxiety, Quality of life, Buruli ulcer disease, Neglected tropical disease
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emotional support, as well as engaging in advocacy, pro-
viding support for decision making and peer support, and 
helping with advance care planning; offering respite ser-
vices; and engaging in activities to foster intrinsic capac-
ity’ [22]. In this study, a caregiver was defined as a person 
who provided such assistance to a BUD patient with 
either active or past infection. The study was conducted 
in three rural districts in Ghana namely; Asante Akim 
North, Ahafo Ano North (both districts in the Ashanti 
region) and Upper Denkyira East (Central region).
Participant recruitment and sampling
BUD patients with active infection and their caregiv-
ers visiting BUD clinics for medical care were identified 
and recruited using a convenience sampling technique. 
For the recruitment of BUD patients with past infec-
tion, the hospital records of these patients were retrieved 
and they were contacted and informed of the study and 
subsequently invited to participate in their community 
setting. In addition, age and sex matched healthy indi-
viduals residing in BUD endemic communities were 
also contacted and recruited as controls using conveni-
ence sampling. Participants were provided with informa-
tion leaflets informing them of the study. This was read 
and explained in the local language of Twi to those who 
were unable to read. Caregivers and healthy controls 
were included in the study if they had been resident in a 
BUD endemic community for more than two years, and 
were aged 18 to 60  years. Participants were excluded if 
they had a known physical or psychiatric illness that 
could confound study results. In addition, persons 
aged < 18  years and those unable to respond to ques-
tions were excluded. All participants provided written 
informed consent.
Data tools
The data collection tools (Additional file  1) used in this 
study were chosen to allow comparison with the results 
of previous psychological [19, 20] and quality of life [4] 
studies of BUD, along with consideration to BUD-specific 
instruments and those recommended in the NTD Toolkit 
[23].
WHO Quality of Life-BREF (WHOQOL-BREF), is an 
international cross-culturally comparable QoL assess-
ment scale used to evaluate people’s perception of their 
quality of life in relation to their personal goals, concerns 
and culture. It consists of 26 items which measure across 
4 domains: physical health, psychological health, social 
relationships and the environment. The score for each 
item ranges from 1 to 5 and the total score for a domain 
is from 20 to 100 with higher scores indicating greater 
QoL [24–27].
WHO Disability Assessment Schedule (WHODAS) 
2.0 and the Buruli Ulcer Functional Limitation Score 
(BUFLS) were employed to assess the degree of func-
tional limitation and participation in BUD patients. 
The WHODAS 2.0 generally assesses functioning in 6 
domains; cognition, mobility, self-care, relationships, 
life activities and participation in community activities 
[28]. Scores for each item on WHODAS 2.0 range from 
0 to 4. The scores of items across each domain are com-
puted with higher scores representing higher functional 
limitation.
BUFLS was designed and validated in Benin and Ghana 
[29] and is specifically used for assessing functional limi-
tation in BUD. It consists of items related to the perfor-
mance of 19 common daily activities. Each item is scored 
between 0 and 2 (0 = can perform activities easily, 1 = dif-
ficulties in performing activities and 2 = cannot perform 
activities at all). Functional limitation score is calculated 
by summing the individual item scores and dividing by 
the maximum possible score for an individual and finally 
multiplied by 100. Higher scores indicate more functional 
limitations with range between 0 and 100%. A score was 
not calculated if more than 6 items were not applicable.
Self-reporting questionnaire SRQ-20 is a 20-item scale 
used to screen for symptoms of mental distress. The 
score for each item ranges from 0 (symptom absent) to 
1 (symptom present). Score items are summed to obtain 
the total score. Score above cut-off point indicates prob-
able mental distress [30]. A cut-off score of 8 is widely 
used, however optimal cut off ranges vary across lan-
guages and settings [31–33]. In this study, we cautiously 
used 5 as our cut-off point to detect distress that may be 
present in BUD patients with pre-ulcerative forms.
Hospital Anxiety and Depression Scale (HADS) was 
chosen to screen for anxiety and depression among the 
study population. The HADS tool assesses two subscales 
(anxiety and depression) with scoring for each item rang-
ing from 0 to 3 (0 = lowest anxiety or depression level; 
3 = highest anxiety or depression level). A total subscale 
of 0–7 indicates an absence of anxiety and/or depres-
sion; scores 8–10 indicate mild symptoms of either anxi-
ety and/or depression; scores 11–14 indicate moderate 
symptoms of anxiety and/or depression; scores 15–21 
indicate severe symptoms of anxiety and/or depression 
[34].
Tool translation
To our knowledge, the above data tools had not previ-
ously been used in the local Twi language. In keeping 
with WHO guidance on research tool use in different 
languages [35], all data tools were first translated into 
Twi by a professional linguistics tutor (MO) familiar with 
the mental health issues addressed by the various data 
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tools. Next, the translated tools (Additional file  2) were 
reviewed and portions back-translated by the study coor-
dinator (NA) and study research assistant (MNO). Minor 
changes were made to better reflect items in the origi-
nal English language tools. All staff involved in the study 
then received training on questionnaire administration 
and conduction of interviews. The study team later dis-
cussed and tested the translated versions of the data tools 
on seven patients at the Agogo BUD clinic for compre-
hensibility, acceptability and relevance of the items. No 
major changes were considered necessary.
Data collection
Data collection took place between 1st August and 30th 
November 2019 in the BUD clinics and communities 
within the selected districts in Ghana. Face-to-face inter-
views were conducted using the study data tools; inter-
views lasted between 45 and 60  min. For BUD patients 
with active and past infection, WHODAS, WHOQOL, 
SRQ-20, HADS, and BUFLS were administered, while 
WHOQOL, SRQ-20, and HADS were used for caregiv-
ers and controls. The HADS tool was only administered 
to participants who scored ≥ 5 on the SRQ-20 (screen-
ing) tool. Persons who scored < 5 were deemed unlikely to 
have a common mental disorder (anxiety or depression) 
and so were not administered the HADS tool. Interviews 
for patients with active infection and their caregivers were 
conducted in private in the BUD treatment clinic. Inter-
views for participants with past infection and controls 
were conducted in health facilities located within the 
communities. All interviews were conducted in private 
and confidentiality was maintained at all times. Scores 
were computed according to the scoring manual for each 
data tool. Results were entered in Microsoft Excel ver-
sion 2013 (Microsoft Corporation, Redmond, WA, USA) 
before being exported to STATA (Stata Corp LP, College 
Station, Texas, USA) for further analysis.
Statistical analysis
Study data was analysed using STATA version 14.0. 
Descriptive statistics were used to summarize the charac-
teristics of the study participants. In addition, the degree 
of association was evaluated using student t test and chi-
square (χ2) or Fisher’s exact tests, where appropriate, with 
a  P  value of ≤ 0.05 deemed to be statistically significant. 
Mean quality of life scores are reported with their respec-
tive 95% confidence intervals. All items on a Likert scale 
were assessed using mean scores. Each item response was 
scored into 3 different groups: ‘can do easily/at baseline 
level’; ‘can do with difficulty’; and ‘cannot do at all’. Scores 
were summarized using frequencies and percentage scores 
in a bar chart.
Results
The results of this study have been reported in accord-
ance with the STROBE checklist (Additional file 3).
Characteristics of study participants and the occurrence 
of functional limitations
In all, 129 participants consisting of 26 patients with 
active BU infection, 29 with past infection, 38 car-
egivers, and 36 controls were recruited into the study. 
Among the study participants, the median age was 
34  years [interquartile range (IQR): 23–42], and 
71 (55%) were females. 73 (65%) participants were 
employed, 10 (9%) were in education, and 19 (17%) 
were unemployed. Table  1 shows 45 (83%) BUD 
patients with active or past infection patients had 
ulcerated lesions, while 9 patients (17%) had pre-ulcer-
ated lesions. For patients with BUD (active and past 
infection), lesions were most commonly located on the 
lower limbs in 29 (59%) individuals, with 14 (29%) hav-
ing lesions on the upper limb. Six (12%) BUD patients 
had lesions on other parts or in multiple locations. 
There was significant limitation of lower limb move-
ment in BUD patients with active infection compared 
to past infection (Table  2): toe movement (P = 0.011); 
knee movement (P = 0.028); and ankle movement 
(P = 0.011). There were no significant differences in 
the range of movement in the upper limbs of BUD 
patients with active infection when compared to past 
infection. Compared with past infection, more persons 
with active infection experienced limitation in per-
forming basic activities (Fig.  1). The presence of pain 
(P = 0.012), ulcer (P = 0.0), and dry scar (P = 0.0) were 
significantly associated with functional limitation in all 
BUD patients (Table 3).
Assessment of the domains of quality of life
Figure  2 and Additional file  4 show domain scores 
of quality of life assessments. In the physical health 
domain, mean QoL scores were 54 ± 11.1 and 56 ± 11.0 
(95% CI: 49.5‒58.5 and 52.2‒59.7) respectively for par-
ticipants with active infection and controls. Similarly in 
the psychological domain, scores were lower for active 
infection than controls [57.1 ± 15.2 (95% CI: 50.9‒63.2) 
vs 64.7 ± 11.6 (95% CI: 60.8‒68.6)]. Participants with 
past infection had high QoL scores in both physical 
[61.3 ± 13.5 (95% CI: 56.1‒66.5)] and psychological 
health domains [68.4 ± 14.6 (95% CI: 62.7‒74.0)]. There 
was a significant difference in domains between BUD 
patients with active and past infection: physical health 
(P = 0.036); psychological scores (P = 0.007); social rela-
tionships (P = 0.001); and environmental (P = 0.001). 
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There were also significant differences in psychological 
(P = 0.029), social relationships (P = 0.001) and envi-
ronment domain scores (0.019) between BUD patients 
with active infection and healthy controls, although 
there was no statistical difference in the physical health 
domain (P = 0.504). Figure  2 shows higher median 
scores for participants with past BU infection in physi-
cal health domain compared to controls.
Distribution and assessment of mental distress 
among study participants
Compared to controls, BUD patients (active and past infec-
tion) were more likely to have mental distress as assessed 
using the SRQ-20. Statistically significant differences 
were found in a total of 11/20 SRQ-20 questions, includ-
ing feeling nervous (P = 0.001), inability to think clearly 
(P = 0.013), being unhappy (P = 0.001), feeling frightened 
(P = 0.013), and thinking of ending life (P = 0.04) (Table 4).
The proportion of the depression and anxiety among 
study participants was assessed using the HADS tool. 
Depression (P = 0.003) was more common in participants 
with active and past BU infection, compared to controls 
(Table  5). Depression and anxiety were present in 4/38 
(11%) and 6/38 (16%) of caregivers respectively.
Relationship between functional limitation and mental 
disorders among BUD patients
Tables  6 and 7 show the associations between func-
tional limitation and common mental health conditions 
Table 1 Socio demographic and clinical characteristics of study participants
N/A not applicable, BUD Buruli ulcer disease
*Variable contains missing data
BUD experience, n (%)
Characteristics Active infection Past infection Caregiver Control All
Number recruited 26 (20) 29 (22) 38 (30) 36 (28) 129 (100)
Sex
Male 13 (50) 13 (45) 14 (37) 18 (50) 58 (45)
Female 13 (50) 16 (55) 24 (63) 18 (50) 71 (55)
Age (years)*
≤ 20 7 (27) 6 (23) 0 (0) 4 (11) 17 (15)
21‒30 4 (15) 7 (27) 6 (24) 11 (31) 28 (25)
31‒40 4 (15) 5 (19) 8 (32) 14 (39) 31 (27)
41‒50 6 (23) 2 (8) 5 (20) 4 (11) 17 (15)
≥ 51 5 (20) 6 (23) 6 (24) 3 (8) 20 (18)
Occupation*
Unemployed 6 (24) 8 (32) 1 (4) 4 (11) 19 (17)
Farmer 16 (64) 7 (28) 20 (80) 16 (44) 60 (54)
Artisan 0 (0) 2 (8) 0 (0) 5 (14) 7 (6)
Student 2 (8) 4 (16) 0 (0) 4 (11) 10 (9)
Other occupation 1 (4) 6 (24) 2 (8) 2 (6) 6 (5)
Lesion type*
Ulcer 21 (81) 24 (86) N/A N/A 45 (83)
Oedema 2 (8) 2 (7) N/A N/A 4 (7)
Nodule 2 (8) 0 (0) N/A N/A 2 (4)
Plaque 1 (3) 2 (7) N/A N/A 3 (6)
Lesion location*
Upper limb 4 (16) 10 (42) N/A N/A 14 (29)
Lower limb 19 (76) 10 (42) N/A N/A 29 (59)
Buttocks and perineum 0 (0) 1 (4) N/A N/A 1 (2)
Head and neck 1 (4) 0 (0) N/A N/A 1 (2)
Back 1 (4) 0 (0) N/A N/A 1 (2)
Lower limb and back 0 (0) 2 (8) N/A N/A 2 (4)
Upper and lower limb 0 (0) 1 (4) N/A N/A 1 (2)
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Table 2 Limitation of movement in affected body part in BUD 
with active and past infection
*Variable contains missing data; **P < 0.05, BUD Buruli ulcer disease
Affected part Active infection
n = 26 (%)
Past infection
n = 29 (%)
P value
Yes No Yes No
Lower limb*
Toe movement is 
reduced
10 (40) 15 (60) 3 (10) 26 (90) 0.011**
Knee movement is 
reduced
6 (24) 19 (76) 1 (4) 27 (97) 0.028**
Ankle movement is 
reduced
7 (28) 18 (72) 1 (3) 28 (97) 0.011**
Hip movement is 
reduced
1 (4) 24 (96) 1 (3) 28 (97) 0.92
Upper limb*
Thumb movement is 
reduced
1 (4) 24 (96) 1 (3.45) 28 (97) 0.92
Wrist movement is 
reduced
2 (8) 23 (92) 4 (14) 25 (86) 0.50
Shoulder movement is 
reduced
0 (0) 25 (100) 1 (3) 28 (97) 0.35
Finger movement is 
reduced
2 (8) 23 (92) 2 (7) 27 (93) 0.88
Hand movement is 
reduced
1 (4) 24 (96) 3 (10) 26 (90) 0.38
Elbow movement is 
reduced
2 (8) 23 (92) 4 (14) 25 (86) 0.50
(anxiety and depression) in patients with active and 
past BU infection. In participants with active BU infec-
tion, depression was linked to limitation in clothing and 
personal care (P = 0.039) (Table  6), whilst anxiety was 
not linked to functional limitations (Table 7). In partici-
pants with past BU infection, depression was associated 
with limitation in clothing and personal care (P = 0.048) 
and limitation in mobility (P = 0.004) (Table  6), with 
anxiety also being associated with limitation in mobility 
(P = 0.018) (Table 7).
Discussion
This study holistically assessed the impact of BUD on 
patients (active infection as well as past infection) and 
their caregivers simultaneously. With these findings, we 
show BUD imparts substantial burden on the mental 
health of affected patients (active and past infection) and 
their caregivers when compared to controls.
In this BUD cohort, most patients had single lesions 
located on the lower limbs in keeping with the known 
epidemiology of the disease in West Africa [36]. In addi-
tion, significant levels of functional limitations in the 
lower limbs were observed in patients with active BU 
infection compared to patients with past BU infection. 
Factors associated with functional limitations in BUD 
included the presence of pain, ulcers and dry scars. Most 
patients with active infection presented with ulcers on 
the lower limbs and were more likely to have pain; this 
may account for the observed difference in functional 
limitation in the lower limbs of patients with past infec-
tion and those with active infection. Adequate man-
agement of pain is essential to minimise functional 
limitation in patients with active infection. Interventions 
aimed at preventing disability should be an integral part 
of BUD management as they significantly improve the 
overall skin condition, reduce pain, and subsequent func-
tional limitations [37]. The Mental Wellbeing and Stigma 
Task Group (MWS) established by the Neglected Tropi-
cal Disease/Non-Governmental Organization/Network 
(NNN) encourages BUD control programmes to con-
tinually seek opportunities for integrating the mental and 
physical health of individuals with NTDs including BUD 
[6]. Such recommendations have been echoed by the 
WHO in its recent global health policy manual [7]. These 
efforts, ranging from the creation of local support groups 
to more formal inclusion of psychological services for 
affected individuals, will sustainably promote the inclu-
sion and well-being of people living with NTDs such as 
BUD.
Mental distress was more prevalent in all BUD patients 
(active and past infection) and their caregivers, compared 
to controls. Depression [borderline (mild) and abnormal 
(moderate/severe) HADS score] was found in 27% (7/26) 
of active BU infection, 17% (5/26) of past BU infection, 
and 11% (4/38) of caregivers, compared to 0% (0/36) of 
controls. Anxiety [borderline (mild) and abnormal (mod-
erate/severe) HADS score] was found in 42% (11/26) of 
active BU infection, 20% (6/29) of past BU infection, and 
16% (6/38) of caregivers, compared to 14% (5/36) of con-
trols. These findings for active and past BU infection are 
in keeping with previous psychological studies in BUD, 
which showed symptoms of anxiety in pre-ulcer states in 
66.7% and 61.5% of ulcer states for active infection [19], 
and 19.5% anxiety and 31.7% depression for past infec-
tion [20].The disabling, disfiguring, and stigmatizing 
conditions associated with most NTDs results in mental 
distress in affected persons, and may result in persist-
ing social participation restrictions even among BUD 
patients with past infection [10]. It is therefore not sur-
prising that BUD patients with past infection have pre-
viously expressed a need to continue to access holistic 
case, including counselling services [38, 39]. Most BUD 
patients and caregivers showed signs of mental distress 
such as fear, sadness, nervousness as a result of the dis-
ease. These results are also in keeping with similar studies 
on mental burden of caregivers and patients with NTDs 
[15, 17, 19, 40].
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Table 3 Factors associated with functional limitation in BUD patients
*Variable contains missing data; **P < 0.05, BUD Buruli ulcer disease
Characteristics Active infection
n = 26 (%)
Past infection
n = 29 (%)
P value
Level of education* 0.1
None 6 (26) 6 (21)
Primary and/or middle school 17 (74) 17 (60)
Secondary and/or above 0 (0) 5 (18)
Dominant side* 0.08**
Right 22 (96) 22 (79)
Left 1 (4) 6 (21)
Pain* 0.012**
Yes 21 (91) 15 (60)
No 2 (9) 10 (40)
When is your pain worse* 0.17
Day 6 (26) 6 (40)
Night 6 (26) 1 (7)
Same all the time 11 (48) 8 (53)
Ulcer* 0
Yes 20 (91) 2 (9)
No 2 (9) 21 (91)
Scar is dry* 0
Yes 1 (6) 21 (84)
No 15 (94) 4 (16)
Sticking / adhering scar* 0.25
Yes 4 (25) 2 (8)
No 12 (75) 23 (92)
Fig1 Functional limitations identified in BUD patients. A intensity of functional limitation faced by active BUD patients in performing basic activities. 
B Intensity of functional limitation faced by BUD patients with past infection in performing basic activities. Bar graphs show the extent of functional 
limitations experienced by BUD patients with active infection compared to past infection in performing basic activities. BUD: Buruli ulcer disease
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We explored the relationship between functional lim-
itations in BUD affected individuals and the presence of 
co-morbid mental disorders. From our results, a range 
of functional limitations were associated with anxiety 
and depression among BUD patients (active and past 
infection). Importantly, limitation in movement in past 
infection was associated with both anxiety and depres-
sion. One explanation for this finding may be that the 
scars of past infection led to an inability to move freely, 
impairing the participant’s ability to carry out daily 
activities and negatively impacting other aspects of the 
individual’s life, leading to reduced overall productiv-
ity and mental distress. Secondly, it was observed that 
patients with active infection and limitation in cloth-
ing and personal care were significantly associated 
with depression. It can be assumed that the necrotiz-
ing wounds on the skin of patients makes it difficult to 
effectively take care of themselves without external sup-
port, which could result in feelings of embarrassment 
and subsequent depression. Furthermore, the stig-
matizing ulcers prevent patients from dressing freely 
without having to expose BUD affected body parts. Dif-
ficulty in mobility as well as clothing and personal care 
was also associated with depression in BUD patients 
with past infection. Early appropriate medical interven-
tion and provision of disability prevention services have 
been shown to reduce functional limitation in affected 
body parts [1, 37]. In addition, the early diagnosis and 
treatment of BUD patients is likely to limit the extent 
of the skin lesions, thereby preventing disability, and 
reducing the stigma, quality of life, and mental health 
impact of BUD [41].
NTDs have been associated with poor QoL in affected 
individuals. We assessed QoL using WHOQoL based 
Fig. 2 Quality of life (QoL) domain assessments of study participants. A Perception of QoL in physical health; B Perception of QoL in psychological 
health; C Perception of QoL in social relationships; D Perception of QoL in the environment. Box plots show the QoL assessments of study 
participants across the QoL domains. The box plots were constructed as median, minimum and maximum values, and interquartile ranges. The 
middle horizontal line represents the median distribution while the lower and upper ends of the box denote the 25th and 75th percentile of 
participants’ responses in each domain. The green box plots represent the raw scores while the red and blue box scores represent transformed 
scores of 4–20 and 0–100 respectively. BUD: Buruli ulcer disease
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on the scores of 4 domains (physical health, psycho-
logical, social, and environmental). It was observed that 
active BUD participants had the lowest QoL scores out 
of the groups studied. QoL expressed by an individual 
is dependent on a host of intrinsic and extrinsic factors 
[42]. The disabling conditions coupled with the stigma 
BUD affected individuals face may have accounted 
for the perceived low QoL. Though caregivers are not 
themselves physically affected by the disease, the signifi-
cant amount of time and resources they devote to caring 
for their sick BUD relatives, as well as the distress they 
may face in this role, greatly impacts their quality of life 
as shown in our results. Interestingly, median scores of 
participants with past BUD infection were higher than 
those of healthy controls in the physical health domain. 
While these differences were not statistically significant, 
it is still surprising given the otherwise clear trends in 
distress and mental health conditions in past infected 
patients compared to controls. The participants with 
past infection in this study on the whole had less func-
tional limitations than those with active infection, which 
could explain why quality of life was higher than active 
infection. The QoL results were comparable to those in a 
study of former Buruli ulcer patients with early, complete 
treatment, and small Buruli ulcers [4]. Such results could 
be explained by a positive change in perspective follow-
ing treatment, a psychological phenomenon known as 
response shift [43]. In addition, it is also possible healthy 
controls may have been facing some challenges unrelated 
to BUD, which could have influenced how they perceived 
their quality of life.
Study strengths and limitations
While this study has documented significant mental dis-
tress and a high rate of anxiety and depression among BUD 
Table 5 Distribution of anxiety and depression in study 
participants using HADS tool
HADS Hospital Anxiety and Depression Scale
*P < 0.05
HADS items Active 
infection
n = 26 (%)
Past 
infection 
n = 29 (%)
Control
n = 36 (%)
P value
Depression
Normal 19 (73) 24 (83) 36 (100) 0.003*
Mild 6 (23) 3 (10) 0 (0)
Moderate/
severe
1 (4) 2 (7) 0 (0)
Anxiety
Normal 15 (58) 23 (79) 31 (86) 0.136
Mild 6 (23) 3 (10) 2 (6)
Moderate/
severe
5 (19) 3 (10) 3 (8)
Table 4 Assessment of mental distress in study participants using SRQ‑20
*P < 0.05
SRQ items Active infection
n = 26 (%)
Past infection
n = 29 (%)
Control
n = 38 (%)
P value
Headache 16 (62.0) 21 (72.4) 20 (55.6) 0.374
Lack of appetite 6 (23.1) 3 (10.3) 4 (11.1) 0.310
Sleeping problems 10 (38.5) 8 (27.6) 7 (19.4) 0.254
Being frightened 17 (65.4) 13 (44.8) 10 (27.8) 0.013*
Shaking hands 6 (23.1) 5 (17.2) 2 (5.6) 0.133
Feeling nervous 13 (50.0) 11 (37.9) 3 (8.3) 0.001*
Poor digestion 4 (15.4) 4 (13.8) 1 (2.8) 0.154
Not thinking clearly 9 (34.6) 4 (13.8) 2 (5.6) 0.013*
Being unhappy 16 (61.5) 12 (41.4) 6 (16.8) 0.001*
Crying more than normally 11 (42.3) 5 (17.2) 0 (0)  < 0.001*
Not enjoying activities 16 (61.5) 4 (14.3) 3 (8.3)  < 0.001*
Difficulty with decision making 9 (34.6) 6 (21.4) 5 (13.9) 0.152
Work suffering 21 (80.8) 10 (34.5) 8 (22.2)  < 0.001*
Not feeling life is useful 7 (26.9) 3 (10.3) 1 (2.8) 0.015*
Loss of interest in life 11 (42.3) 6 (20.7) 4 (11.1) 0.018*
Feeling worthless 9 (34.6) 3 (10.3) 1 (2.8) 0.002*
Thinking of ending life 6 (23.1) 1 (3.5) 2 (5.6) 0.04*
Always feeling tired 8 (30.8) 8 (27.6) 5 (13.9) 0.233
Stomach problems 14 (53.9) 11 (37.9) 8 (22.2) 0.037*
Easily tiring 11 (42.3) 9 (31.0) 8 (22.2) 0.239
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patients and their caregivers in three BUD endemic dis-
tricts in Ghana, there were a number of limitations. Firstly, 
the COVID-19 pandemic resulted in disruptions to NTD 
services (including outreach and case detection activi-
ties) as public health resources were increasingly directed 
towards fighting the pandemic, which impacted recruit-
ment into the study. Secondly, it is important to note 
that up to 40% of BU cases (and a significant proportion 
of caregivers) in West Africa are in children < 15 years old 
[44]. This is significant given that half of mental health con-
ditions start by 14 years of age [45]. Nevertheless, despite 
children not being included in this study, findings of high 
mental health burden among adult patients with active and 
past infection persisted. Thirdly, this study was conducted 
in a low middle-income country and in a local language 
(Twi), and as such results may not be generalizable to 
Table 6 Comparison of association between functional limitation and occurrence of depression in BUD patients (active and past 
infection)
*P < 0.05; Hospital Anxiety and Depression Scale (HADS) scores of 0–7 = normal or no depression present, 8–10 = mild depression, 11–21 = moderate or severe 
depression, BUD Buruli ulcer disease
Active infection
n = 25 (%)
Past infection
n = 29 (%)
Limitation Normal Mild depression Moderate/
severe 
depression




Limitation in food preparation and eating
Yes 13 (52) 6 (24) 1 (4) 0.3 7 (24) 2 (7) 1 (3) 0.39
No 5 (20) 0 (0) 0 (0) 17 (59) 1 (3) 1 (3)
Limitation in clothing and personal care
Yes 5 (20) 5 (20) 0 (0) 0.039* 1 (3) 1 (3) 1 (3) 0.048*
No 13 (52) 1 (4) 1 (4) 23 (79) 2 (7) 1 (3)
Working limitation
Yes 13 (52) 6 (24) 0 (0) 0.07 6 (21) 2 (7) 1 (3) 0.28
No 5 (20) 0 (0) 0 (0) 18 (62) 1 (3) 1 (3)
Limitation in mobility
Yes 16 (64) 6 (24) 1(4) 0.66 1 (3) 2 (7) 1 (3) 0.004*
No 2 (8) 0 (0) 0 (0) 23 (79) 1 (3) 1 (3)
Table 7 Comparison of association between functional limitation and occurrence of anxiety in BUD patients (active and past 
infection)
HADS Hospital Anxiety and Depression Scale, BUD Buruli ulcer disease
*P value < 0.05; HADS scores of 0–7 = normal or anxiety present, 8–10 = mild anxiety, 11–21 = moderate/ severe anxiety
Active infection, n = 25 (%) Past infection, n = 29 (%)
Limitation Normal Mild anxiety Moderate/
severe anxiety
P value Normal Mild anxiety Moderate/
severe anxiety
P value
Limitation in food preparation and eating
Yes 10 (40) 6 (24) 4 (16) 0.34 7 (24) 2 (7) 1 (3) 0.46
No 4 (16) 0 (0) 1 (4) 16 (55) 1 (3) 2 (7)
Limitation in clothing and personal care
Yes 4 (16) 3 (12) 3 (12) 0.40 1 (3.45) 1 (3.45) 1 (3.45) 0.12
No 10 (40) 3 (12) 2 (8) 22 (75.86) 1 (3.45) 1 (3.45)
Working limitation
Yes 11 (44) 3 (12) 5 (20) 0.15 6 (21) 2 (7) 1 (3) 0.36
No 3 (12) 3 (12) 0 (0) 17 (59) 1 (3) 2 (7)
Limitation in mobility
Yes 12 (48) 6 (24) 5 (20) 0.43 2 (7) 0 (0) 2 (7) 0.018*
No 2 (8) 0 (0) 0 (0) 21 (72) 3 (10) 1 (3)
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other socio-economic and cultural settings. Additionally, 
information on variables such as socio-economic status/ 
income levels, alcohol use, tobacco use and family history 
of mental illness were not collected. Thus we are unable 
to determine the impact of such factors on the observed 
mental distress in participants.
Despite the limitations, this study has several strengths. 
This is the first study to simultaneously assess mental 
distress in BUD patients and their caregivers. The study 
included a control group of health individuals to allow for 
the assessment of the background levels of mental dis-
tress. Cases and controls were largely matched in terms of 
their demographic characteristics. Controls were selected 
from the communities from which BUD cases resided. 
Thus it is well likely that their socio-economic status 
would not be significantly different as their employment 
status were similar. However, we cannot be truly certain 
about this as no information on income levels were col-
lected. Further research in other BUD endemic countries 
within different socio-economic settings and including 
younger age groups is therefore warranted.
Conclusions
BUD results in a significant mental health and quality 
of life burden on both patients and caregivers alike. Evi-
dence-based measures aimed at preventing disability and 
functional limitation should be encouraged in order to 
improve the mental health and quality of life of affected 
individuals. Our findings support the recommendation 
for integration of psychosocial interventions in BUD 
management for patients with active and past BU infec-
tion, as well as their caregivers.
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